// App-Quantinova.ai

[FRI0330] : SAFETY AND EFFICACY OF CANAKINUMAB IN FREQUENTLY FLARING GOUTY ARTHRITIS PATIENTS WHO ARE CONTRAINDICATED, INTOLERANT OR UNRESPONSIVE TO NON-STEROIDAL ANTI- INFLAMMATORY DRUGS AND/OR COLCHICINE: RESULTS FROM 3 YEARS FOLLOW-UP

Researchers

Presenter

  • R. Alten

Principal Investigators

  • T. Bardin

  • M. Bloch

  • K. Lheritier

  • U. Machein

  • G. Junge

  • A. So

  • N. Schlesinger

Medical Centers

  • Holdsworth House Medical Practice, Sydney, NSW, Australia

  • Centre Hospitalier Universitaire Vaudois and Lausanne University Hospital, Lausanne, Switzerland

  • Charite-University Medicine Berlin, Berlin, Germany

  • Hopital Lariboisiere, Paris, France

  • Rutgers-NJMS, Newark, New Jersey, United States

Locations

  • Germany

  • Switzerland

  • Australia

  • United States

  • France

Companies

  • Novartis AG

Study Components

Therapeutic Area

  • Infectious Diseases (ID)

Disease

  • Gout

  • Osteoporosis

  • Inflammatory Arthritis

  • Sepsis

Biomarkers

  • High sensitivity C-reactive protein

Drug/Treatment

  • canakinumab (SC)

  • Colchicine

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved